Is BioLife Solutions (BLFS) overvalued or fairly valued?

MarketChacha shows BioLife Solutions's valuation in context — a forward P/E of about 94.7, a price-to-book of about 4.1 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is BioLife Solutions's revenue?

BioLife Solutions reported revenue of $96.2M for FY2025, with net profit of $-4.6M, per official filings.

What is the share price of BioLife Solutions (BLFS)?

BioLife Solutions last traded at $31.24 (+7.0% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

BioLife Solutions

BLFS · NYSE · Healthcare · United States

$31.24+7.0%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 7:27 PM

Snapshot

TickerBLFS

ExchangeNYSE

SectorHealthcare

IndustryMedical Instruments & Supplies

CountryUnited States

Employees155

HeadquartersBothell, United States

Market cap$1.5B

P/B4.1

Volume8.88M

Websitewww.biolifesolutions.com

Filings tracked4

About BioLife Solutions

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Profile as reported by Yahoo Finance.

Who owns it

Insiders2.4%
Institutions97.6%
Public & other0.0%

291 institutional holders

As reported by Yahoo Finance.

Top holders

T. Rowe Price Investment Management, Inc.13.32%
Blackrock Inc.12.49%
Casdin Capital, LLC12.19%
Invesco Ltd.4.81%
Vanguard Capital Management LLC3.93%
State Street Corporation3.23%
FMR, LLC3.01%
Massachusetts Financial Services Co.2.45%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

Forensic scorecard

Latest ROE of -1.2% is on the low side — the business earns a modest return on shareholder capital.

Net margin trend-100.0% → -4.8%

Margin has expanded by about 95.2 points — the business is getting more profitable.

Return on equity-1.2%

Latest ROE of -1.2% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $29.0M · EPS 0.07

Est. earnings growth +66.9%

Next fiscal year

Rev $134.6M · EPS 0.33

Est. earnings growth +32.0%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$17.8652-wk range$31.49

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Market cap

$1.5B

Day change

+7.0%

Fwd P/E

94.7

P/B

4.1

Beta

1.94

Revenue (FY2025)

$96.2M

Net margin

-4.8%

ROE

-1.2%

Revenue CAGR (2y)

+18.9%

EPS (FY2025)

-0.10

Net profit (FY2025)

$-4.6M

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about BLFS

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$96.2M	$-4.6M	-0.10	-4.8%	-1.2%
FY2024	$74.6M	$-20.2M	-0.44	-27.0%	-5.8%
FY2023	$68.0M	$-68.0M	-1.55	-100.0%	-20.1%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$27.5M	$1.2M	0.02	4.3%
2025Q3	$28.1M	$621,000	0.01	2.2%
2025Q2	$25.4M	$-15.8M	-0.33	-62.3%
2025Q1	$22.1M	$-448,000	0.00	-2.0%
2024Q3	$21.4M	$-1.7M	-0.04	-8.0%
2024Q2	$19.7M	$-20.7M	-0.45	-105.1%
2024Q1	$18.4M	$-10.2M	-0.22	-55.4%
2023Q3	$23.6M	$-29.1M	-0.67	-123.6%
2023Q2	$29.2M	$-10.2M	-0.23	-34.9%
2023Q1	$37.7M	$-13.7M	-0.32	-36.4%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Reg FD disclosure, Exhibits
SEC6/3/2026material
8-K — Results of operations, Exhibits
SEC5/7/2026material
10-Q filing
SEC5/7/2026
10-K/A filing
SEC4/28/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.